Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C.
In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ordem dos Médicos
1992-12-01
|
| Series: | Acta Médica Portuguesa |
| Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307 |
| _version_ | 1797996888774934528 |
|---|---|
| author | A Tavares M Galvão |
| author_facet | A Tavares M Galvão |
| author_sort | A Tavares |
| collection | DOAJ |
| description | In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with special attention to their safety, and mention the new perspectives of treatment with recombinant DNA FVIII:C and ultimately by gene insertion therapy. |
| first_indexed | 2024-04-11T10:23:28Z |
| format | Article |
| id | doaj.art-250fb9b9532341339f9bcd54bbb91efe |
| institution | Directory Open Access Journal |
| issn | 0870-399X 1646-0758 |
| language | English |
| last_indexed | 2024-04-11T10:23:28Z |
| publishDate | 1992-12-01 |
| publisher | Ordem dos Médicos |
| record_format | Article |
| series | Acta Médica Portuguesa |
| spelling | doaj.art-250fb9b9532341339f9bcd54bbb91efe2022-12-22T04:29:39ZengOrdem dos MédicosActa Médica Portuguesa0870-399X1646-07581992-12-0151110.20344/amp.3307Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C.A Tavares0M GalvãoServiço Imuno.Hemoterapia, Hospital de Santa Maria, Lisboa.In the last thirty years, factor VIII concentrates have been the mainstay of hemophilia treatment, first as wet cryoprecipitate and later as dry concentrates commercially available. The evidence of a high risk of blood-born virus transmission by these products provoked the development of new methods for virus inactivation. We report these methods with special attention to their safety, and mention the new perspectives of treatment with recombinant DNA FVIII:C and ultimately by gene insertion therapy.https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307 |
| spellingShingle | A Tavares M Galvão Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C. Acta Médica Portuguesa |
| title | Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C. |
| title_full | Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C. |
| title_fullStr | Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C. |
| title_full_unstemmed | Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C. |
| title_short | Segurança terapêutica na hemofilia A. Inactivação viral dos concentrados de FVIII:C. |
| title_sort | seguranca terapeutica na hemofilia a inactivacao viral dos concentrados de fviii c |
| url | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/3307 |
| work_keys_str_mv | AT atavares segurancaterapeuticanahemofiliaainactivacaoviraldosconcentradosdefviiic AT mgalvao segurancaterapeuticanahemofiliaainactivacaoviraldosconcentradosdefviiic |